Bevacizumab biosimilar (Kashiv BioSciences)

贝伐珠单抗生物类似药 (Kashiv BioSciences)

Report date: 2025/05/06 15:48:44

Base Information

Drug NameBevacizumab biosimilar (Kashiv BioSciences)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAdello Biologics Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAdello Biologics Llc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A